KEGG    Network variation - SARS coronavirus 2 (SARS-CoV-2)
[ Network menu | Network entry | Help ]
ENTRYnt06171
NameSARS coronavirus 2 (SARS-CoV-2)
CategoryDisease view; Viral infection
Pathwayhsa05171 Coronavirus disease - COVID-19
GenomeT40361
DiseaseH02398 COVID-19
Display drug-target relation   disease type
RLR signaling
N00469      RNA→RIGI→MAVS→TRAF3→(TANK+NAP1+SINTBAD..→(TBK1+IKBKE)→(IRF7,IRF3)⇒(IFNA,IFNB1)
N01310              nsp13⊣TBK1
N01320              nsp3⊣ISG15=IRF3
N01319                (nsp6,ORF6)⊣IRF3
N01308      RNA→(MDA5,ZNFX1)→MAVS→TRAF3→(TANK+NAP1+SINTBAD..→(TBK1+IKBKE)→(IRF7,IRF3)⇒(IFNA,IFNB1)
N01309    nsp3⊣ISG15=MDA5
 
Complement cascade
N01491      [C4,C2]−((MBL2,COLEC10/11,..→[C4b,C2a]→(C4b+C2a)
  D1,D2,D3,D4,D5,D6,D7,D8,D9,D10,D11
 |		  
N01312      S→(MBL2+MASP1/2)
N01487      [C4,C2]−((C1QA,C1QB,C1QC)+..→[C4b,C2a]→(C4b+C2a)
D1,D2,D3,D4,D5,D6,D7,D8,D9,D10,D11
 |		    
N01314    S→(IgG,IgM)→((C1QA,C1QB,C1QC)+..
N01315      F2−((MBL2,COLEC10/11,..→F2a
N01502        FG−(F2a,((MBL2,COLEC1..→Fibrin
  D1,D2,D3,D4,D5,D6,D7,D8,D9,D10,D11
 |		  
N01316      (S,N)→(MBL2,COLEC10/11,F..
 
IFN signaling
N00150    (IFNA,IFNB1)→(IFNAR1+IFNAR2)→(JAK1,TYK2)→(STAT1+STAT2+IRF9)⇒(IRF7,EIF2AK2)
N01321        (nsp1,nsp6,nsp13,O..⊣STAT1
N01322        (nsp6,nsp13,ORF7a,..⊣STAT2
 
Translation
N01317      40S=mRNA=60S
N01318    nsp1⊣40S
 
Angiotensin II signaling
N01306        AngII→AGTR1→NOX2→ROS→NFKB→(VCAM1,IL6,MMP2,MM..
D1,D2,D3,D4,D5,D6,D7,D8,D9,D10,D11
 |		              
N01307    S⊣ACE2⊣AngII→AGTR1→NOX2→ROS→NFKB→(TNF,IL6,IL1B,IL12..


Drug name
D1D11944Etesevimab (USAN)
D2D11971Tozinameran (JAN)
D3D12014Sotrovimab (USAN/INN)
D4D12114Elasomeran (JAN)
D5D12115COVID-19 vaccine (ChAdOx1-S [recombinant])
D6D12129COVID-19 vaccine (Ad26.COV2-S [recombinant])
D7D12142Casirivimab and imdevimab
D8D12241Regdanvimab (INN)
D9D12336SARS-CoV-2 Spike glycoprotein vaccine antigen nvx-cov2373
D10D12610Ufrenmeran (JAN/INN)
D11D12738Zapomeran (JAN/INN)